Cwm LLC Has $191,000 Position in Royalty Pharma plc (NASDAQ:RPRX)

Cwm LLC lifted its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 42.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,796 shares of the biopharmaceutical company’s stock after acquiring an additional 2,014 shares during the period. Cwm LLC’s holdings in Royalty Pharma were worth $191,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Xponance Inc. raised its position in Royalty Pharma by 38.8% during the third quarter. Xponance Inc. now owns 18,218 shares of the biopharmaceutical company’s stock valued at $494,000 after purchasing an additional 5,090 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Royalty Pharma by 75.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 209,576 shares of the biopharmaceutical company’s stock valued at $5,612,000 after purchasing an additional 90,282 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Royalty Pharma by 103.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 79,990 shares of the biopharmaceutical company’s stock worth $2,171,000 after buying an additional 40,582 shares in the last quarter. Inspire Investing LLC bought a new stake in shares of Royalty Pharma during the 3rd quarter worth $364,000. Finally, TD Asset Management Inc lifted its position in shares of Royalty Pharma by 49.4% during the 3rd quarter. TD Asset Management Inc now owns 290,483 shares of the biopharmaceutical company’s stock worth $7,884,000 after buying an additional 96,026 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on RPRX. StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, April 11th. JPMorgan Chase & Co. decreased their price target on shares of Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating on the stock in a report on Tuesday, February 20th. Bank of America dropped their price objective on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, April 12th. Finally, The Goldman Sachs Group decreased their target price on shares of Royalty Pharma from $56.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, February 20th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $46.75.

Royalty Pharma Stock Performance

NASDAQ:RPRX opened at $28.41 on Friday. The stock’s 50-day moving average is $29.36 and its 200-day moving average is $28.58. Royalty Pharma plc has a 1-year low of $25.92 and a 1-year high of $35.70. The company has a current ratio of 7.90, a quick ratio of 7.90 and a debt-to-equity ratio of 0.61. The stock has a market cap of $16.97 billion, a P/E ratio of 15.03 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.03 by $0.12. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. The business had revenue of $736.00 million for the quarter, compared to the consensus estimate of $702.90 million. Equities research analysts anticipate that Royalty Pharma plc will post 3.95 earnings per share for the current year.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 17th will be paid a $0.21 dividend. The ex-dividend date is Thursday, May 16th. This represents a $0.84 annualized dividend and a dividend yield of 2.96%. Royalty Pharma’s dividend payout ratio is 44.44%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.